Form D · Biotechnology
Principal Technologies Inc.
Vancouver, A1 · CIK 0002105516
Offering snapshot reported Jul 17, 2026 · SEC filing
- Reported sold
- $91.9K Offering amount: $91.9K
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2026 | Initial | $91,900 | No comparison | 6 | SEC filing |
| Apr 16, 2026 | Initial | $325,338 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-591219
The US dollar amounts are based on the Bank of Canada average rate of exchange reported on July 9, 2026, which was USD$1=CDN$1.4169.
Source: Form D, filed Jul 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Mckeown | Executive |
| Peter Mc Keown | Executive |
| Leopold Specht | Director |
| Gerald Trent | Director, Executive |
| Alfred Von Liechtenstein | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2500 700 West Georgia Street
Vancouver, A1, V7Y 1B3
Phone: 587-225-2599
Vancouver, A1, V7Y 1B3
Phone: 587-225-2599